Construction of a prognostic model and immune landscape analysis for lung adenocarcinoma utilizing a bioinformatics signature derived from acrolein-related genes, and identification of associated subtypes.
- 1Department of Thoracic Surgery, YiWu Central Hospital, No.519, Nanmen Street, Jiangdong Sub-district, Yiwu, 322000, Zhejiang, China.
- 2Department of Thoracic Surgery, YiWu Central Hospital, No.519, Nanmen Street, Jiangdong Sub-district, Yiwu, 322000, Zhejiang, China. [email protected].
Abstract
Background
Lung adenocarcinoma (LUAD) is driven by the interplay between inherited genetic factors and environmental exposures. Acrolein, a ubiquitous pollutant and major cigarette smoke constituent, induces DNA damage driving pulmonary carcinogenesis. However, acrolein exposure-related genes (AERGs) and their role in LUAD prognosis and immune modulation remain poorly characterized.Methods
A bioinformatics prognostic model was constructed leveraging an eight-gene signature derived from previously reported AERGs. A series of analytical steps were then performed: differential expression using limma, followed by univariate and Least Absolute Shrinkage and Selection Operator Cox regression to address multicollinearity, culminating in the identification of eight core genes via multivariate Cox regression for risk score construction. CIBERSORT and Single-sample Gene Set Enrichment Analysis algorithms were used to evaluate immune microenvironment heterogeneity, and molecular subtypes were characterized via non-negative matrix factorization clustering. Prognostic utility was further assessed with a nomogram, and potential therapeutic agents were predicted through the CellMiner database.Results
In this study, eight core AERGs were identified and used to construct a highly robust prognostic model for LUAD, which demonstrated satisfactory accuracy in survival prediction through both internal and external validation. Based on this gene signature, two molecular subtypes with distinct immune profiles were identified. The high-risk subtype exhibited a "cold tumor" phenotype, characterized by enrichment of M0 macrophages, reduced immune scores, and enhanced immune evasion potential. Conversely, the low-risk subtype exhibited a more immunologically active profile. Notably, the high-risk group also featured higher tumor mutational burden and enhanced sensitivity to conventional chemotherapies, including cisplatin and docetaxel.Conclusion
Integrating multi-omics data, this study established an AERG-based prognostic model for LUAD and systematically evaluated its potential for outcome prediction and personalized immunotherapy guidance.
Related
- Identification of ionizing-radiation-exposure-associated hub genes and a five-gene prognostic signature for pediatric medulloblastoma: An integrated bioinformatics study
- Identification of SLC15A3 as a shared prognostic biomarker for AML and COVID-19 via integrative bioinformatics, machine learning and Mendelian randomization
- Identification of genes associated with a macrophage polarization-related transcriptional signature as biomarkers for tendinopathy based on bioinformatics analysis
- Identification of candidate selenium-associated transcriptomic biomarkers in chronic obstructive pulmonary disease: an integrated bioinformatics and expression validation study
- Identification of Genes Associated with Gut Microbiota Metabolites in Type 2 Diabetes Mellitus Complicated by Acute Cerebral Infarction Based on Bioinformatics and Mendelian Randomization
BibTeX
@article{chen2026construction,
title = {{Construction of a prognostic model and immune landscape analysis for lung adenocarcinoma utilizing a bioinformatics signature derived from acrolein-related genes, and identification of associated subtypes.}},
author = {Jian Chen and Yin Fu and Jiangwei Hu and Junming He},
journal = {Journal of cardiothoracic surgery},
year = {2026},
month = aug,
doi = {10.1186/s13019-026-04646-0},
url = {https://europepmc.org/article/MED/42972360},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Construction of a prognostic model and immune landscape analysis for lung adenocarcinoma utilizing a bioinformatics signature derived from acrolein-related genes, and identification of associated subtypes.
AU - Jian Chen
AU - Yin Fu
AU - Jiangwei Hu
AU - Junming He
PY - 2026
DA - 2026/08/06
JO - Journal of cardiothoracic surgery
DO - 10.1186/s13019-026-04646-0
UR - https://europepmc.org/article/MED/42972360
AB - Background Lung adenocarcinoma (LUAD) is driven by the interplay between inherited genetic factors and environmental exposures. Acrolein, a ubiquitous pollutant and major cigarette smoke constituent, induces DNA damage driving pulmonary carcinogenesis. However, acrolein exposure-related genes (AERGs) and their role in LUAD prognosis and immune modulation remain poorly characterized.Methods A bioinformatics prognostic model was constructed leveraging an eight-gene signature derived from previously reported AERGs. A series of analytical steps were then performed: differential expression using limma, followed by univariate and Least Absolute Shrinkage and Selection Operator Cox regression to address multicollinearity, culminating in the identification of eight core genes via multivariate Cox regression for risk score construction. CIBERSORT and Single-sample Gene Set Enrichment Analysis algorithms were used to evaluate immune microenvironment heterogeneity, and molecular subtypes were characterized via non-negative matrix factorization clustering. Prognostic utility was further assessed with a nomogram, and potential therapeutic agents were predicted through the CellMiner database.Results In this study, eight core AERGs were identified and used to construct a highly robust prognostic model for LUAD, which demonstrated satisfactory accuracy in survival prediction through both internal and external validation. Based on this gene signature, two molecular subtypes with distinct immune profiles were identified. The high-risk subtype exhibited a "cold tumor" phenotype, characterized by enrichment of M0 macrophages, reduced immune scores, and enhanced immune evasion potential. Conversely, the low-risk subtype exhibited a more immunologically active profile. Notably, the high-risk group also featured higher tumor mutational burden and enhanced sensitivity to conventional chemotherapies, including cisplatin and docetaxel.Conclusion Integrating multi-omics data, this study established an AERG-based prognostic model for LUAD and systematically evaluated its potential for outcome prediction and personalized immunotherapy guidance.
SN - 1749-8090
ER -